



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0


F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

**UTN801** : Endometrium normal adjacent tissue (NAT) and endometrium cancer tissue array, including pathology grade, TNM and clinical stage, 79 cases/80 cores (1.5 mm).

Microarray Panel	Endometrium tissue and endometrium carcinoma tissue microarray, containing 70 case endometrium tissue (25 secretory endometrium tissue, 44 proliferative endometrium tissue, 1 endometrium tissue), 9 endometrioid adenocarcinoma, 1 adenosquamous carcinoma, single core per block	
Cores	80	<b>UTN801 H&amp;E</b> 
Cases	79	
Row number	8	
Column number	10	
Core Diameter (mm)	1.5	
Thickness (µm)	5	
QA/QC	H&E, IHC Vimentin	
Tissue Array Type	FFPE	
Species	Human	
Applications	Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.	
Notes	<p>1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). <b>To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C.</b> before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.</p> <p>In the following specsheet, “*” means invalid core; “-” means no applicable or negative in IHC markers.</p>	

	1	2	3	4	5	6	7	8	9	10
A	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
B	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
C	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
D	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
E	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
F	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
G	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
H	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Adr

**Legend:** Ute - Uterus

● - Malignant tumor, 
 ● - Malignant tumor (stage I), 
 ● - Malignant tumor (stage IB), 
 ● - Malignant tumor (stage IC), 
 ● - Malignant tumor (stage II), 
 ● - Malignant tumor (stage IIA), 
 ● - NAT

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	54	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
A2	2	46	F	Uterus	Intermediate stage proliferative endometri...	-	-	-	NAT	
A3	3	46	F	Uterus	Early stage secretory endometrium tissue	-	-	-	NAT	
A4	4	52	F	Uterus	Early-intermediate stage secretory endometri...	-	-	-	NAT	
A5	5	45	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	



E1	41	12	F	Uterus	Advanced stage proliferative endometrium tis sue	-	-	-	NAT	
E2	42	57	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
E3	43	58	F	Uterus	Early stage proliferative endometrium tissue o f No.75	-	-	-	NAT	
E4	44	42	F	Uterus	Intermediate stage proliferative endometriu... issue	-	-	-	NAT	
E5	45	28	F	Uterus	Intermediate-advanced stage secretory endo metrium tissue	-	-	-	NAT	
E6	46	48	F	Uterus	Intermediate stage proliferative endometriu... issue	-	*	-	NAT	
E7	47	42	F	Uterus	Early stage proliferative endometrium tissue	-	*	-	NAT	
E8	48	48	F	Uterus	Intermediate-advanced stage proliferative end ometrium tissue	-	-	-	NAT	
E9	49	31	F	Uterus	Intermediate stage secretory endometrium tis sue	-	-	-	NAT	
E10	50	51	F	Uterus	Intermediate stage secretory endometrium tis sue	-	-	-	NAT	
F1	51	27	F	Uterus	Early stage secretory endometrium tissue	-	-	-	NAT	
F2	52	35	F	Uterus	Advanced stage secretory endometrium tissue	-	-	-	NAT	
F3	53	36	F	Uterus	Early stage secretory endometrium tissue	-	-	-	NAT	
F4	54	30	F	Uterus	Intermediate stage secretory endometrium tis sue	-	-	-	NAT	
F5	55	52	F	Uterus	Intermediate-advanced stage proliferative end ometrium tissue	-	-	-	NAT	
F6	56	47	F	Uterus	Advanced stage proliferative endometrium tis sue	-	-	-	NAT	
F7	57	51	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
F8	58	42	F	Uterus	Early stage secretory endometrium tissue	-	-	-	NAT	
F9	59	58	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
F10	60	36	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
G1	61	41	F	Uterus	Intermediate stage secretory endometrium tis sue	-	-	-	NAT	
G2	62	43	F	Uterus	Advanced stage proliferative endometrium tis sue	-	-	-	NAT	
G3	63	38	F	Uterus	Intermediate stage secretory endometrium tis sue	-	-	-	NAT	
G4	64	42	F	Uterus	Intermediate stage secretory endometrium tis sue (sparse)	-	-	-	NAT	
G5	65	52	F	Uterus	Intermediate stage proliferative endometriu... issue	-	-	-	NAT	
G6	66	54	F	Uterus	Advanced stage proliferative endometrium tis sue	-	-	-	NAT	
G7	67	56	F	Uterus	Intermediate stage proliferative endometriu... issue	-	-	-	NAT	
G8	68	57	F	Uterus	Intermediate stage secretory endometrium tis sue	-	-	-	NAT	
G9	69	50	F	Uterus	Intermediate stage proliferative endometriu... issue	-	-	-	NAT	
G10	70	45	F	Uterus	Early stage proliferative endometrium tissue	-	-	-	NAT	
H1	71	52	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	IC	Malignant	
H2	72	62	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
H3	73	48	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	IB	Malignant	
H4	74	34	F	Uterus	Endometrioid adenocarcinoma	T2aN0M0	1	IIA	Malignant	
H5	75	58	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	IC	Malignant	
H6	76	55	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1--2	IC	Malignant	
H7	77	56	F	Uterus	Endometrioid adenocarcinoma	T2aN0M0	*	IIA	Malignant	
H8	78	74	F	Uterus	Endometrioid adenocarcinoma	T2N0M0	2--3	II	Malignant	
H9	79	54	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2--3	IC	Malignant	

H10	80	66	F	Uterus	Adenosquamous carcinoma	T1N0M0	-	I	Malignant	
-	0	42	M	Adrenal gland	Pheochromocytoma (tissue marker)		-		Malignant	



TNM grading:

T - Primary tumor

- Tx - Primary tumor cannot be assessed
- T0 - No evidence of primary tumor
- Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
- T1 - Tumor invades submucosa
- T2 - Tumor invades muscularis propria
- T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
- T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes

- Nx - Regional lymph nodes cannot be assessed
- N0 - No regional lymph node metastasis
- N1 - Metastasis in 1 to 3 regional lymph nodes
- N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis

- Mx - Distant metastasis cannot be assessed
- M0 - No distant metastasis
- M1 - Distant metastasis